Quick Takeaways
- GLAZER CAPITAL, LLC filed SCHEDULE 13G/A for Revance Therapeutics, Inc. Common Stock, par value $0.001 per share (RVNC).
- Disclosed ownership: 0%.
- Date of event: 31 Mar 2025.
GLAZER CAPITAL, LLC - 31 Mar 2025 SCHEDULE 13G/A Report for Revance Therapeutics, Inc. Common Stock, par value $0.001 per share (RVNC)
- Filing Manager
- GLAZER CAPITAL, LLC
- Reporting Manager
- Glazer Capital, LLC
- Symbol
- RVNC
- Disclosed Ownership
- 0 shares
- Ownership
- 0%
- Form type
- SCHEDULE 13G/A
- Filing time
- 15 May 2025, 16:33:38 UTC
- Date of event
- 31 Mar 2025
- Previous filing
- 06 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"GLAZER CAPITAL, LLC disclosed 0% ownership in Revance Therapeutics, Inc. Common Stock, par value $0.001 per share (RVNC) on 31 Mar 2025."
What Changed
- Previous schedule filing date: 06 Feb 2025.
- Current filing was accepted on 15 May 2025, 16:33.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Glazer Capital, LLC | 0% | 0 | 0 | 0 | Paul J. Glazer | Paul J. Glazer, Managing Member | |
| Paul J. Glazer | 0% | 0 | 0 | 0 | Paul J. Glazer | Paul J. Glazer |